Grace Therapeutics, Inc. (GRCE) - 10-K Summary
Business Context and Reporting Period
Company: Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2025
Business Overview: A clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies for rare and orphan diseases. The company recently completed a domestication from Canada to Delaware (October 2024) and changed its name. It operates with a lean workforce of six full-time employees as of March 31, 2025.
Key Financial Metrics
| Metric (in thousands) | Year Ended Mar 31, 2025 | Year Ended Mar 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9,568) | $(12,853) |
| Loss Per Share (Basic & Diluted) | $(0.79) | $(1.35) |
| Research & Development Expenses | $9,511 | $4,683 |
| General & Administrative Expenses | $7,168 | $6,684 |
| Cash and Cash Equivalents (Ending) | $22,133 | $23,005 |
| Net Cash Used in Operating Activities | $(14,904) | $(12,333) |
| Net Cash Provided by Financing Activities | $14,032 | $7,359 |
Liquidity: As of March 31, 2025, the company held $22.1 million in cash. Management believes this is sufficient to fund operations for at least 12 months from the issuance date of the report (June 2025), extending into the third quarter of 2026.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $3.3 million (25.6%) primarily due to a $5.9 million favorable change in the fair value of derivative warrant liabilities and the absence of $1.5 million in restructuring costs incurred in the prior year.
- Increased R&D Spend: R&D expenses increased by $4.8 million (103%) driven by the pivotal Phase 3 STRIVE-ON safety trial for the lead candidate GTx-104.
- Capital Raise: In February 2025, the company completed a private placement raising net proceeds of $13.7 million, compared to $7.3 million in the prior year.
- Corporate Restructuring: The company completed a domestication from Canada to Delaware and a name change to Grace Therapeutics, Inc. in October 2024.
Guidance, Outlook, and Risks
Strategic Focus: The company has prioritized the development of GTx-104 (injectable nimodipine for aneurysmal subarachnoid hemorrhage) and de-prioritized GTx-102 and GTx-101 pending additional funding or partnerships.
Clinical Milestones:
- GTx-104: The Phase 3 STRIVE-ON trial met its primary endpoint in February 2025, showing a 19% reduction in clinically significant hypotension compared to oral nimodipine. The company plans to submit a New Drug Application (NDA) to the FDA in the second quarter of 2025.
- GTx-102 & GTx-101: Further development is contingent on securing additional funding or strategic partnerships.
Outlook: The company expects to incur significant expenses and continued operating losses. Additional capital will be required to fund the commercial launch of GTx-104 (if approved) and daily operations beyond mid-2026.
Key Risks:
- Capital Dependency: Heavy reliance on additional financing to continue operations and commercialization.
- Regulatory Uncertainty: Success depends on FDA approval of GTx-104 via the 505(b)(2) pathway.
- Single Product Focus: Business viability is heavily dependent on the success of GTx-104.
- Going Concern: While currently funded for 12+ months, the company has an accumulated deficit of $220.7 million and no history of commercial sales.
Investor Verification Checklist
- NDA Submission Timeline: Verify the actual filing date of the GTx-104 NDA (targeted Q2 2025) and FDA acceptance status.
- Cash Runway: Monitor quarterly cash burn rates to confirm the 12-month liquidity projection remains valid.
- Derivative Warrant Liability: Review the fair value of outstanding warrants (classified as liabilities) as stock price volatility significantly impacts net income/loss.
- Commercialization Plan: Assess the company's strategy and capital requirements for building a sales force if GTx-104 receives approval.
- De-prioritized Assets: Track any progress on licensing or selling GTx-102 and GTx-101 to generate non-dilutive capital.